Patents
Patents for A61P 21 - Drugs for disorders of the muscular or neuromuscular system (23,287)
06/2004
06/09/2004EP1196176B1 Use of beta-napthoquinone derivatives for the manufacture of a medicament having an inhibiting effect on the release of glutamate by the brain
06/09/2004CN1503667A Carbamate compounds for use in preventing or treating neurodegenerative disorders
06/09/2004CN1152863C Substituted pyridines as selective coclooxygenase-2-inhibitors and composition thereof
06/08/2004US6747042 N-heterocyclic derivatives useful for treating or preventing neuronal damage associated with neurological disease
06/08/2004US6747031 N-heterocyclic derivatives as NOS inhibitors
06/08/2004US6747024 Inhibiting calpain and/or reactive oxygen species in warm-blooded animals
06/08/2004CA2307552C Substituted pyridine compounds as anti-inflammatory agents
06/03/2004WO2004045635A1 Muslce building preparation
06/03/2004WO2004006830A3 Use of ccn protein family members for the treatment of disorder associated to an altered calcium and/or sodium flux
06/03/2004WO2003086371A3 Use of ep4 receptor ligands in the treatment of il-6 involved diseases
06/03/2004WO2003084937A3 Pyrimidinedione derivatives useful for the treatment of inflammation and immunological diseases
06/03/2004WO2003051842A3 Compositions decreasing activity of hormone-sensitive lipase
06/03/2004US20040107453 Multipotent adult stem cells, sources thereof, methods of obtaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof
06/03/2004US20040106778 Interferon gamma-like protein
06/03/2004US20040106668 Immunosuppressive effects of administration of a cyclooxygenase-2 inhibitor, a leukotriene B4 receptor inhibitor and a cyclosporin
06/03/2004US20040106652 such as (2S)-3,3-dimethyl-1-[2-(5-phenylpentanoyl) pyrrolidinyl]pentane-1,2-dione which has affinity for immunophilin; for treatment of neurological disorders/neurodegenerative diseases; nerve growth factors; FK binding proteins
06/03/2004US20040106651 3,4-diaminopyriding tartrate and phosphate, pharmaceutical compositions and uses thereof
06/03/2004US20040106628 CX3CR1 receptor antagonists useful in the treatment or prophylaxis of neurodegenerative disorders, demyelinating disease and pain
06/03/2004US20040106625 Therapeutic agents useful for treating pain
06/03/2004US20040106616 To treat one or more conditions responsive to capsaicin receptor modulation, such as pain, itch, urinary incontinence, cough, hiccup, and/or obesity
06/03/2004US20040106604 Novel pyrrole derivatives as pharmaceutical agents
06/03/2004US20040106574 4-substituted with a imidazo[1,2a]pyrid-3-yl or pyrazolo[2,3a]pyrid-3-yl ring
06/03/2004US20040106558 Hydroxamate-containing cysteine and serine protease inhibitors
06/03/2004US20040106196 Systems and methods for treating patients with processed lipoaspirate cells
06/03/2004US20040106155 Method for kidney disease treatment by drug intervention
06/02/2004EP1424330A1 Activator for peroxisome proliferator-responsive receptor delta
06/02/2004EP1423697A2 Secreted proteins
06/02/2004EP1423511A2 Nucleic-acid associated proteins
06/02/2004EP1423509A2 Differentiation of neural stem cells and therapeutic use thereof
06/02/2004EP1423436A2 Use of heparinoid derivatives for treating and diagnosing diseases that can be treated by heparinoids
06/02/2004EP1423422A2 A caspase- 8 binding protein, its preparation and use
06/02/2004EP1423406A2 Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina)
06/02/2004EP1423390A2 Purine inhibitors of phosphodiesterase (pde) 7
06/02/2004EP1423388A2 2-arylamino-pyrimidines for the treatment of gsk3-related disorders
06/02/2004EP1423380A1 Pyrazole-derived kinase inhibitors and uses thereof
06/02/2004EP1423133A2 Treatment of muscular dystrophies and related disorders
06/02/2004EP1423132A2 Complex mixtures exhibiting selective inhibition of cyclooxygenase-2
06/02/2004EP1423121A1 Cysteine protease inhibitors with 2-cyano-4-amino-pyrimidine structure and cathepsin k inhibitory activity for the treatment of inflammations and other diseases
06/02/2004EP1423119A1 Heterobicycles fkbp-ligands
06/02/2004EP1423107A2 Fatty alcohol drug conjugates
06/02/2004EP1423106A1 Arylsulfonyl derivatives with 5-ht 6 receptor affinity
06/02/2004EP1423012A2 Isolation and mobilization of stem cells expressing vegfr-1
06/02/2004EP1227824B1 Transplant/implant device and method for its production
06/02/2004CN1501937A Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
06/02/2004CN1501915A Bipiperidinyl-derivatives and their use as chemokine receptor inhibitors
06/02/2004CN1501911A Phenethanolamine derivatives for treatment of respiratory diseases
06/02/2004CN1501806A Method for preparing an extract of ginkgo biloba leaves highly enriched in active principles
06/02/2004CN1501798A Medicinal compositions comprising diclofenac and ornoprostil
06/02/2004CN1500810A Fibroblast growth factor-2 analogue, producing process and application thereof
06/02/2004CN1500809A Fibroblast growth factor-2 analogue, producing process and application thereof
06/02/2004CN1500781A Inhibitors of interleukin-1 beta converting enzyme
06/02/2004CN1151822C Liquid medicine for treating traumatic injury
06/02/2004CN1151804C Use of Whiteflower Leadword Root
06/01/2004USRE38524 Dipeptide derivatives as growth hormone secretagogues
06/01/2004US6743816 Imidazole derivatives with anti-inflammatory activity
06/01/2004US6743807 Cyclic β-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-α
06/01/2004US6743788 Carbamate and oxamide compounds
06/01/2004US6743781 Glycerolipid compounds useful for the transfer of an active substance into a target cell
06/01/2004US6743415 Delivery of anti-migraine compounds through an inhalation route
05/2004
05/27/2004WO2003088985A8 Use of compositions containing petasites for treating diseases
05/27/2004WO2003073986A3 Aminoalkylphosphonates and related compounds as edg receptor agonists
05/27/2004WO2003059276B1 Novel mammalian multipotent stem cells and compositions, methods of preparation and methods of administration thereof
05/27/2004WO2003004604A3 Phage displayed pdz domain ligands
05/27/2004WO2003002109A3 Use of tyrosine kinase inhibitors for treating autoimmune diseases
05/27/2004WO2002060480A9 Methods for treating or preventing skin disorders using cd2-binding agents
05/27/2004US20040102630 For therapy of cancer, auto-immune diseases, cardiovascular diseases, infectious diseases, nephrological diseases, neurodegenerative diseases and viral infections
05/27/2004US20040102508 Naphathalene derivatives which bind to the ep4 receptor
05/27/2004US20040102506 Pyrazole compositions useful as inhibitors of ERK
05/27/2004US20040102483 Chemical compounds
05/27/2004US20040102481 Benzenesulfonic acid indol-5-yl esters as antagonists of the 5-ht6 receptor
05/27/2004US20040102460 Phosphodiesterase 4 inhibitors
05/27/2004US20040101911 Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors
05/27/2004US20040101882 Secreted proteins
05/26/2004EP1422217A2 Aminocyclohexyl ether compounds and uses thereof
05/26/2004EP1421948A2 Use of botulinum toxins for treating sweating in humans
05/26/2004EP1421218A2 Model of autoimmune disease and methods for identifying agents against autoimmune disease
05/26/2004EP1421198A2 Cell-based high-throughput screening methods
05/26/2004EP1421174A2 Hematopoietic cell e-selection/l-selectin ligand polypeptides and methods of use thereof
05/26/2004EP1421108A2 Antimicrobial and anti-inflammatory peptides
05/26/2004EP1420800A1 Modulation of insulin-regulated aminopeptidase (irap)/angiotensin iv (at 4) receptor activity
05/26/2004EP1420798A2 Treatment and prevention of heat shock protein-associated diseases and conditions
05/26/2004EP1420795A1 As-needed administration of an androgenic agent to enhance female sexual desire and responsiveness
05/26/2004EP1420794A1 Prostaglandin analogs as chloride channel opener
05/26/2004EP1420783A1 Stable emulsion composition
05/26/2004EP1420773A1 Amidine derivatives for treating amyloidosis
05/26/2004EP1420772A2 Use of beta-adrenoceptor agonists for the treatment of neurodegenerative diseases
05/26/2004CN1500097A Human monoclonal antibodies to FC Alpha receptor (CD89)
05/26/2004CN1500095A Polymer conjugates of neublastin and methods of using ssame
05/26/2004CN1500082A Cyano-5ubstituted dihydropyrimidine compounds and their use to treat diseases
05/25/2004US6740777 Mercaptoalkyl benzoic acid derivative are useful for inhibiting naaladase (acetylated alpha-linked acidic dipeptidase/n-/) enzyme activity
05/25/2004US6740672 Administering alosetron, tropisetron, ondansetron, granisetron and/or bemesetron
05/25/2004US6740666 Substituted 8-arylquinoline phosphodiesterase-4 inhibitors
05/25/2004US6740655 3',5'-cyclic nucleotide phosphodiesterase 4-specific inhibitors reduce eosinophil influx to the lungs; side effect reduction; antiinflammatory agent; antiallergens; respiratory system disorders, especially asthma
05/25/2004US6740309 Delivery of compounds for the treatment of migraine through an inhalation route
05/25/2004US6740308 Composition comprising condensation aerosol formed by volatilizing antihistamine under conditions effective to produce heated vapor and condensing to form condensation aerosol particles having less than 5% degradation products
05/25/2004US6740307 Delivery of β-blockers through an inhalation route
05/21/2004WO2004041258A2 Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses
05/21/2004WO2003084935A3 Diaryl pyrimidinone derivatives useful for the treatment of inflammation and immunogolical diseases
05/21/2004WO2003080105A3 Angiogenesis regulator genes, pharmaceutical preparations containing same and uses thereof
05/21/2004CA2503716A1 Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses